AIM ImmunoTech Enrolls And Doses First Subject In Phase 2 Study Evaluating Ampligen For The Treatment Of Post-COVID Conditions
Portfolio Pulse from Happy Mohamed
AIM ImmunoTech Inc. has enrolled and dosed the first subject in its Phase 2 study evaluating Ampligen as a potential treatment for post-COVID conditions. The study, expected to be completed in Q4 2023, is a major milestone for the company. Preliminary data suggests Ampligen could be an effective treatment option for post-COVID conditions. The study will enroll approximately 80 subjects aged 18 to 60 years across up to 10 centers in the United States.
July 10, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AIM ImmunoTech's initiation of Phase 2 study for Ampligen as a potential treatment for post-COVID conditions could potentially boost the company's stock in the short term, especially if preliminary data continues to show promise.
The initiation of a Phase 2 study is a significant milestone for any biotech company, often leading to increased investor interest and potentially a rise in stock price. Given the global impact of COVID-19 and the urgent need for effective treatments, positive preliminary data could further drive investor interest in AIM ImmunoTech.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100